Tyme Technologies Securities Lawsuit Investigation

Our attorneys are investigating legal claims on behalf of investors of Tyme Technologies (NASDAQ: TYME) regarding possible violations of federal securities laws.

Invest in Tyme Technologies (NASDAQ: TYME)?

You may have a legal claim.  Speak to an attorney about your rights.


Tyme Technologies Stock Plunges 35% Following Publication of Clinical Trial Results

On January 18, 2019, it was reported that a clinical trial of potential Tyme product, “SM-88,” which is intended to treat end-stage pancreatic cancer, showed that SM-88 may improve mortality rates for those treated with the therapy. More recently, some have reported that the trial did not include a control group, a generally accepted metric by which the scientific community measures progress through comparison. The reports state that Tyme instead compared survival data to historic trends.

With this reporting, Tyme’s stock price fell $1.32 per share, or 35.39% to $2.41 on the same day, January 18 2019.  Since then, it has continued to decrease in price and is currently valued at $2.13 as of January 23, 2019.

Gibbs Law Group's Financial Fraud Experience

Gibbs Law Group’s financial fraud and securities lawyers have more than two decades of experience prosecuting fraud. Our attorneys have successfully litigated against some of the largest companies in the United States, and we have recovered more than a billion dollars on our clients’ behalf.

We have fought some of the most complex cases brought under federal and state laws nationwide, and our attorneys have been recognized with numerous awards and honors for their accomplishments, including Top 100 Super Lawyers in Northern California, Top Plaintiff Lawyers in California, The Best Lawyers in America, and rated AV Preeminent (among the highest class of attorneys for professional ethics and legal skills).

titan of plaintiffs bar award
best law firm ranking
chambers USA leading firms award
daily journal top plaintiff lawyers award

Noteworthy Financial Fraud Cases

American Express Financial Advisors Securities Litigation$100 million cash settlement for clients alleging American Express steered them into under-performing “shelf space funds” to reap kickbacks
Chase Bank “Check Loan” Litigation$100 million settlement for consumers alleging Chase offered long-term fixed-rate loans, only to later more-than-double required payments
Peregrine Financial Group Customer LitigationSettlements worth $75 million for futures and commodities investors who lost millions in the collapse of Peregrine Financial Group, Inc.
NantHealthCourt-appointed Co-Lead Counsel in a securities class action alleging the company’s founder violated federal securities law and artificially inflated stock prices

Our Securities Attorneys

Jason Gibbs

Eric has served in leadership positions in a number of high profile, complex financial lawsuits. He has been recognized as a Daily Journal, among the Top 100 Super Lawyers in Northern California, and a Law360 MVP for Consumer Protection.

Dave Stein

David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.

Amanda Karl

Amanda represents employees, consumers, and sexual assault survivors in complex class actions. She also leads the firm’s Voting Rights Task Force.

TYME stock losses?

Speak to a securities attorney to recover your money. Free, confidential consultations.